Merck (MRK) Change in Account Payables (2009)

Merck (MRK) reported Change in Account Payables of -$73.0 million for Q4 2009, down 19.67% quarter-over-quarter from -$61.0 million in Q3 2009.

Merck (MRK) Change in Account Payables (2009) Analysis & Trends

Merck (MRK) has 1 years of Change in Account Payables data on file, last reported at -$73.0 million in Q4 2009.

Change in Account Payables for Q4 2009 came in at -$73.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2009 was -$113.0 million (changed N/A YoY), and the FY2025 annual result was $110.0 million, down 39.56% from the prior year.
Change in Account Payables eased to -$73.0 million in Q4 2009 per MRK's latest filing, from -$61.0 million in the prior quarter.
Over five years, Change in Account Payables peaked at -$61.0 million in Q3 2009 and troughed at -$73.0 million in Q4 2009.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change Payables (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn	-
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn	-
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn	-
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn	-
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn	-
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn	571.00 Mn
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn	-67.00 Mn
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn	-
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn	409.00 Mn
10	Novartis Ag	108.28 Bn	107.60 Bn	-	-53.00 Mn

Download Data